← Back to Clinical Trials
Recruiting NCT05833932
Suhexiang Pill for Acute Ischemic Stroke: A Registry Study
Trial Parameters
Condition Ischemic Stroke
Sponsor Dongzhimen Hospital, Beijing
Study Type OBSERVATIONAL
Phase N/A
Enrollment 1,000
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2023-06-01
Completion 2024-12-31
Interventions
Suhexiang Pill
Brief Summary
The primary purpose of this study is to investigate the effectiveness and safety of the Suhexiang Pill for patients with acute ischemic stroke in real-world settings.
Eligibility Criteria
Inclusion Criteria: * Acute ischemic stroke within 7 days of symptom onset. * Age ≥ 18 * Patient who has received Suhexiang Pill treatment * Patient or legally authorized representative has signed informed consent. Exclusion Criteria: * Be allergic to Suhexiang Pill * Known to be pregnant or breastfeeding. * With conditions that render outcomes or follow-up unlikely to be assessed.
Related Trials
NCT06418698
The Correlation of Intracranial Artery Calcification and Outcomes of Mechanical Thrombectomy
View Trial →
NCT06316557
HOPE From the Cerebellum: TMS-Induced Cognitive Recovery After Stroke
View Trial →
NCT06674460
Treatment of Acute Ischemic Stroke With Edaravone Dexborneol Sublingual Tablets in Small Vessel Dise
View Trial →